Conclusions:
Many questions remain as to how best to predict the onset of aCFLD. It is unlikely a single test will reliably detect or diagnose CFHBI, but rather a combination of tests with an algorithmic approach (e.g. blood tests + radiological studies) relying on changes over time rather than strict cut-offs. Elastography methods are currently gaining rapid momentum and soon will likely be incorporated in routine clinical settings. Future methods also include the incorporation of newer biomarkers and other upcoming modalities such as multi-omics, and artificial intelligence (AI)-driven protocols38,70,76.
Table 1 – Summary of non-invasive tests utilized in cystic fibrosis-related hepatobiliary involvement